Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835533 | 1.00 | DGAT1 (0.50) | DGAT1ALDH1A1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL30356854 | 0.88 | DGAT1 (0.43) | DGAT1ALDH1A1HCRTR1HCRTR2KDM4E | |
| SCHEMBL14968084 | 0.87 | DGAT1 (0.50) | DGAT1ALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL669097 | 0.87 | DGAT1 (0.50) | DGAT1ALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL14968065 | 0.87 | DGAT1 (0.50) | DGAT1ALDH1A1KMT2AKDM4ETSHR | |
| SCHEMBL1589689 | 0.87 | DGAT1 (0.48) | DGAT1KMT2AGAAPOLBMEN1 | |
| SCHEMBL4598307 | 0.85 | KMT2A (0.48) | DGAT1ALDH1A1KMT2AKDM4EGAA | |
| SCHEMBL30754857 | 0.84 | LIPE (0.52) | DGAT1HCRTR1GAAPOLB | |
| SCHEMBL14596989 | 0.84 | DPP4 (0.52) | DGAT1ALDH1A1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL1588601 | 0.83 | MAPT (0.55) | DGAT1ALDH1A1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011031628-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-03-17 | — | — | WO | disclosed |
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | DGAT1 2918/4885ALDH1A1 3484/4885KMT2A 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.